More Divestments In Store As Takeda Digests Shire, Faces Expiries
Executive Summary
Takeda remains committed to meeting its post-Shire divestment target, as it faces up to $2bn in at-risk revenues from expiries and seeks additional cost synergies.
You may also be interested in...
Neurocrine Not Giving Up On Luvadaxistat Despite Phase II Miss
Schizophrenia drug licensed from Takeda missed Phase II endpoint for negative symptoms, but hits secondary cognition endpoints. Neurocrine plans to further study compound for cognitive benefits.
Biopharma Quarterly Dealmaking Statistics, Q2 2019
Biopharma companies raised $12.4bn in Q2, largely from follow-on public offerings. In the latest mega-merger of the year, AbbVie spent $63bn on Allergan and its established portfolio. Many of the higher-valued alliances focused on the area of protein degradation.
Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech
Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.